89123-58-0

Usage

Uses

2,3-Diamino-5-bromopyrazine

InChI:InChI=1/C4H5BrN4/c5-2-1-8-3(6)4(7)9-2/h1H,(H2,6,8)(H2,7,9)

Upstream product

• 24241-18-7 2-amino-3,5-dibromopyrazine 

Downstream Products

• 91225-48-8 5-bromo-1-methyl-2-methylthio-1H-imidazo<4,5-b>pyrazine 
• 91225-49-9 6-bromo-4-methyl-2-methylthio-4H-imidazo<4,5-b>pyrazine 
• 91225-47-7 6-bromo-1-methyl-2-methylthio-1H-imidazo<4,5-b>pyrazine 
• 91225-46-6 5-bromo-1,3-dimethyl-1H-imidazo<4,5-b>pyrazine-2(3H)-thione 
• 91225-41-1 5-bromo-1H-imidazo<4,5-b>pyrazine 
• 1361570-47-9 5-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrazine-2,3-diamine 
• 1332875-37-2 5-tert-butyl-4-chloro-2-methyl-2H-pyrazole-3-carboxylic acid (3-amino-5-bromo-pyrazin-2-yl)-amide 
• 882856-62-4 2-bromopyrazino[2,3-b]pyrazine 
• 91225-51-3 2-bromo-6-methylpyrazino<2,3-b>pyrazine 
• 91225-50-2 2-ethoxy-6,7-diphenylpyrazino<2,3-b>pyrazine 

Relevant academic research and scientific papers

New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities

New imidazo[1,2-a]pyrazine derivatives have been synthesized either by direct cyclization from pyrazines or by electrophilic substitutions. The presence of electron donating groups on position 8 greatly enhances the reactivity of the heterocycle towards such reactions on position 3 of the heterocycle. The activities of these derivatives in trachealis muscle relaxation and in inhibiting cyclic nucleotide phosphodiesterase (PDE) isoenzyme types III and IV have been assessed. All compounds demonstrated significantly higher relaxant potency than theophylline. All the derivatives were moderately potent in inhibiting the type IV isoenzyme of PDE but only those with a cyano group on position 2 were potent in inhibiting the type III isoenzyme. Copyright (C) 1999 Elsevier Science Ltd.

Regioselective N-alkylation of some imidazole-containing heterocycles and their in vitro anticancer evaluation

Imidazole-containing heterocycles: Imidazopyridines, imidazopyrimidines and imidazopyra-zines can exist more tautomeric forms than benzimidazoles. Their regioselectivities were determined for N-alkylations with 4-fluorobenzyl bromide under basic conditions (K2CO3) in DMF. We observed that, regioisomers were mainly formed as a mixture in this reaction and N-benzylation occurs at a higher ratio on six membered heterocycles. Their structural assignments were made with the use of two-dimensional 1H–1H NOE (nuclear overhauser effect spectroscopy, NOESY). Complementary structural information was provided by 2D-HMBC spectra of the compounds. Synthesized compounds were tested for in vitro cytotoxic activities against Human colon cancer cell line (HCT-116) and leukemia cell lines (K562 and HL-60) by MTT test. Among them, imidazopyridine analogue 10, bearing bromine atom at the C-6 position of the pyridine moiety, gave the lowest IC50 value with 6–7 μg/mL against all three cancer cell lines.

JAK kinase inhibitor, preparation method thereof, and application in the field of medicines

The application relates to a JAK kinase inhibitor, a preparation method thereof, and an application in the field of medicines and belongs to the field of medical chemistry. In the application, a series of novel small-molecular JAK inhibitors are provided and are represented as the general formula (II). The compounds have better effects and higher safety in prevention or treatment on JAK-related adaptation diseases.

Imidazo-pyrazine medical intermediate preparation method

The invention relates to an imidazo-pyrazine medical intermediate preparation method which comprises the following steps: (a) adding 2-amino-3,5-dibromo pyrazine and ammonium hydroxide into a high pressure kettle, heating to 110 to 150 DEG C under the nitrogen protection, reacting, performing suction filtration after cooling to obtain filter cake and drying to obtain compound II; (b) dissolving the compound II into N,N-dimethyl formamide, dropwise adding triethyl orthoformate and formic acid, heating and refluxing under the nitrogen protection and purifying to obtain compound III; (c) adding the compound III, N-methyl pyrrolidone, ammonium hydroxide and copper sulfate pentahydrate into the other high pressure kettle, heating to 130 to 170 DEG C under the nitrogen protection and purifying to obtain imidazo-pyrazine medical intermediate. Therefore, synthesizing steps of a final product can be reduced, and a yield and a purity are improved.

Preparation method of imidazo-pyrazine medical intermediate

The invention relates to a preparation method of an imidazo-pyrazine medical intermediate. The preparation method comprises the following steps that (a) 2-amino-3,5-dibromo pyrazine and ammonia waterare added into an autoclave, heating is performed under nitrogen protection to reach 110-150 DEG C, reaction is performed, suction filtration is performed to obtain a filter cake after cooling, and drying is performed to obtain a compound II; (b) the compound II is dissolved in N,N-dimethyl formamide, triethyl orthoformate and formic acid are added dropwise, heating reflux is performed under nitrogen protection, and a compound III is obtained through purification; (c) the compound II, N-methyl pyrrolidone, ammonia water and copper sulfate pentahydrate are added into the autoclave, heating is performed under nitrogen protection to reach 130-170 DEG C, reaction is performed, and a compound IV is obtained through purification; (d) 1,4-dioxane and the compound IV are dissolved in an acetic acid solution, a NaNO2 water solution is dropwise added under the condition of ice-water bath, heating is performed to 40-50 DEG C after adding, reaction is performed to separate out solid, and suction filtration and washing are performed. Therefore, the synthesis steps of a final product can be decreased, and accordingly the yield and purify of the product are improved.

NEW TRPA1 ANTAGONISTS

The present invention relates to bicyclic heterocyclic derivatives of Forrmula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1 channel inhibition or antagonism.

BCR-ABL kinase inhibitor and its application (by machine translation)

The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and pharmaceutical composition containing the compounds, and application of the compounds or compositions in drug preparation. The compounds of the present invention have strong inhibitory effect on BCR-ABL kinase, and can be used to treat diseases such as tumors.

INHIBITORS OF JAK

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.